115 related articles for article (PubMed ID: 38234016)
1. Computational insights into overcoming resistance mechanisms in targeted therapies for advanced breast cancer: focus on EGFR and HER2 co-inhibition.
Abdulaziz O; Khan FR; Alharthi NS; Alhuthali HM; Hazazi A; Alzahrani HA; Gharib AF; Alsalmi OA; Hawsawi NM; Alhazmi AY
J Biomol Struct Dyn; 2024 Jan; ():1-12. PubMed ID: 38234016
[TBL] [Abstract][Full Text] [Related]
2. Computational analysis of bevacizumab binding with protein receptors for its potential anticancer activity.
Alsakhen N; Radwan ES; Zafer I; Abed Alfattah H; Shamkh IM; Rehman MT; Shahwan M; Khan KA; Ahmed SA
J Biomol Struct Dyn; 2024 Jan; ():1-21. PubMed ID: 38281913
[TBL] [Abstract][Full Text] [Related]
3. Molecular docking and dynamic simulation to identify potential phytocompound inhibitors for EGFR and HER2 as anti-breast cancer agents.
Prabhavathi H; Dasegowda KR; Renukananda KH; Karunakar P; Lingaraju K; Raja Naika H
J Biomol Struct Dyn; 2022 Jul; 40(10):4713-4724. PubMed ID: 33345701
[TBL] [Abstract][Full Text] [Related]
4. Dual functionality of pyrimidine and flavone in targeting genomic variants of EGFR and ER receptors to influence the differential survival rates in breast cancer patients.
Avti PK; Singh J; Dahiya D; Khanduja KL
Integr Biol (Camb); 2023 Apr; 15():. PubMed ID: 38084900
[TBL] [Abstract][Full Text] [Related]
5. Identification of potential inhibitors of HER2 targeting breast cancer-a structure-based drug design approach.
Singh G; Al-Fahad D; Al-Zrkani MK; Chaudhuri TK; Soni H; Tandon S; Narasimhaji CV; Azam F; Patil R
J Biomol Struct Dyn; 2023 Aug; ():1-18. PubMed ID: 37565730
[TBL] [Abstract][Full Text] [Related]
6. Discovery of potential HER2 inhibitors from
Balogun TA; Iqbal MN; Saibu OA; Akintubosun MO; Lateef OM; Nneka UC; Abdullateef OT; Omoboyowa DA
J Biomol Struct Dyn; 2022; 40(23):12772-12784. PubMed ID: 34514973
[TBL] [Abstract][Full Text] [Related]
7. Identification of HER2 inhibitors from curcumin derivatives using combination of
Saibu OA; Singh G; Olugbodi SA; Oluwafemi AT; Ajayi TM; Hammed SO; Oladipo OO; Odunitan TT; Omoboyowa DA
J Biomol Struct Dyn; 2023; 41(21):12328-12337. PubMed ID: 36752338
[TBL] [Abstract][Full Text] [Related]
8.
Das SK; Deka SJ; Paul D; Gupta DD; Das TJ; Maravi DK; Tag H; Hui PK
J Biomol Struct Dyn; 2022 Sep; 40(15):6857-6867. PubMed ID: 33625319
[TBL] [Abstract][Full Text] [Related]
9. Effect of additional inhibition of human epidermal growth factor receptor 2 with the bispecific tyrosine kinase inhibitor AEE788 on the resistance to specific EGFR inhibition in glioma cells.
Berezowska S; Diermeier-Daucher S; Brockhoff G; Busch R; Duyster J; Grosu AL; Schlegel J
Int J Mol Med; 2010 Nov; 26(5):713-21. PubMed ID: 20878094
[TBL] [Abstract][Full Text] [Related]
10. HER2 stabilizes EGFR and itself by altering autophosphorylation patterns in a manner that overcomes regulatory mechanisms and promotes proliferative and transformation signaling.
Hartman Z; Zhao H; Agazie YM
Oncogene; 2013 Aug; 32(35):4169-80. PubMed ID: 23027125
[TBL] [Abstract][Full Text] [Related]
11. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
Anido J; Matar P; Albanell J; Guzmán M; Rojo F; Arribas J; Averbuch S; Baselga J
Clin Cancer Res; 2003 Apr; 9(4):1274-83. PubMed ID: 12684395
[TBL] [Abstract][Full Text] [Related]
12. Dual-Receptor-Targeted (DRT) Radiation Nanomedicine Labeled with
Yook S; Cai Z; Jeong JJ; Lu Y; Winnik MA; Pignol JP; Reilly RM
Mol Pharm; 2020 Apr; 17(4):1226-1236. PubMed ID: 32022567
[TBL] [Abstract][Full Text] [Related]
13. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
Xia W; Petricoin EF; Zhao S; Liu L; Osada T; Cheng Q; Wulfkuhle JD; Gwin WR; Yang X; Gallagher RI; Bacus S; Lyerly HK; Spector NL
Breast Cancer Res; 2013; 15(5):R85. PubMed ID: 24044505
[TBL] [Abstract][Full Text] [Related]
14. Exploring EGFR inhibitors with the aid of virtual screening, docking, and dynamics simulation studies.
Rehman ZU; Najmi A
J Biomol Struct Dyn; 2023 Sep; ():1-21. PubMed ID: 37707987
[TBL] [Abstract][Full Text] [Related]
15. Identifying novel and potent inhibitors of EGFR protein for the drug development against the breast cancer.
Siddiqui AJ; Jahan S; Patel M; Abdelgadir A; Alturaiki W; Bardakci F; Sachidanandan M; Badraoui R; Snoussi M; Adnan M
J Biomol Struct Dyn; 2023; 41(23):14460-14472. PubMed ID: 36826428
[TBL] [Abstract][Full Text] [Related]
16. '
H Ibraheim M; Maher I; Khater I
J Biomol Struct Dyn; 2023 Sep; ():1-16. PubMed ID: 37753739
[TBL] [Abstract][Full Text] [Related]
17. Potential target identification for breast cancer and screening of small molecule inhibitors: A bioinformatics approach.
Agarwal S; Kashaw SK
J Biomol Struct Dyn; 2021 Apr; 39(6):1975-1989. PubMed ID: 32186248
[TBL] [Abstract][Full Text] [Related]
18. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression.
Umemura S; Takekoshi S; Suzuki Y; Saitoh Y; Tokuda Y; Osamura RY
Oncol Rep; 2005 Aug; 14(2):337-43. PubMed ID: 16012712
[TBL] [Abstract][Full Text] [Related]
19. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies.
Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI
Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960
[TBL] [Abstract][Full Text] [Related]
20. A specific amino acid context in EGFR and HER2 phosphorylation sites enables selective binding to the active site of Src homology phosphatase 2 (SHP2).
Hartman Z; Geldenhuys WJ; Agazie YM
J Biol Chem; 2020 Mar; 295(11):3563-3575. PubMed ID: 32024694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]